Market Cap | 23.02M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -18.28M | Forward P/E | -9.07 | EPS next Y | - | 50D Avg Chg | 63.00% |
Sales | 12.24M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 172.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -30.00% |
Recommedations | 3.00 | Quick Ratio | 0.11 | Shares Outstanding | 22.45M | 52W Low Chg | 559.00% |
Insider Own | 44.43% | ROA | -82.46% | Shares Float | 14.63M | Beta | 1.36 |
Inst Own | 4.18% | ROE | - | Shares Shorted/Prior | 459.95K/503.01K | Price | 2.63 |
Gross Margin | 71.89% | Profit Margin | -117.41% | Avg. Volume | 85,791 | Target Price | - |
Oper. Margin | -34.88% | Earnings Date | Nov 12 | Volume | 42,459 | Change | -2.59% |
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. Biotricity, Inc. is based in Redwood City, California.
HC Wainwright & Co. | Neutral | Nov 20, 23 |
HC Wainwright & Co. | Buy | Jul 5, 23 |